Talkspace, Inc.

As of October 31, 2025, Talkspace, Inc. is considered overvalued with a high P/E ratio of 188 and negative EV to EBITDA, despite short-term outperformance against the S&P 500, indicating a valuation grade shift from very attractive to attractive.

As of October 31, 2025, Talkspace, Inc. is considered overvalued with a high P/E ratio of 188 and poor long-term performance, despite strong short-term returns, leading to a valuation grade shift from very attractive to attractive.

As of October 31, 2025, Talkspace, Inc. is considered attractive but overvalued due to a high P/E ratio of 188 compared to the peer average of 156.07, an EV to EBITDA ratio of -170.31, and a PEG ratio of 1.51, indicating inefficiencies and potential mispricing relative to its growth expectations.

As of October 31, 2025, Talkspace, Inc. is considered overvalued due to its high P/E ratio of 188, a Price to Book Value of 4.85, and poor performance metrics compared to peers, resulting in a shift in valuation grade from very attractive to attractive.

As of October 17, 2025, Talkspace, Inc. is considered overvalued due to its high P/E ratio of 188 and recent underperformance, despite a strong 3-year stock return of 231.13%.

As of October 17, 2025, Talkspace, Inc. is considered overvalued with a P/E ratio of 188 and mixed stock performance, showing a year-to-date return of -10.68% compared to the S&P 500's 13.30%.

As of October 17, 2025, Talkspace, Inc. is considered overvalued with a P/E ratio of 188 and a year-to-date return of -10.68%, significantly underperforming the S&P 500's 13.30%.

As of October 3, 2025, Talkspace, Inc. is considered very attractive due to its undervaluation despite a high P/E ratio of 188, outperforming peers like Fulgent Genetics and Enhabit, with a strong 3-year return of 170.59% compared to the S&P 500's 82.57%.

As of September 12, 2025, Talkspace, Inc. is in a bearish trend with mixed technical indicators, having outperformed the S&P 500 over the past year but underperformed year-to-date.

As of September 8, 2025, Talkspace, Inc. is considered overvalued with a high P/E ratio of 188 and poor operational efficiency, reflected in its negative EV to EBITDA ratio, despite a strong one-year return.

As of May 6, 2025, Talkspace, Inc. is fairly valued with a P/E ratio of 188, despite a year-to-date decline of 10.68%, compared to its peers like Addus HomeCare Corp. at 22.93 and Pediatrix Medical Group, Inc. at 7.64.

As of June 13, 2025, Talkspace, Inc. shows a mildly bullish trend due to positive daily moving averages, though caution is advised from bearish weekly MACD and Bollinger Bands, while monthly indicators suggest potential long-term strength.

Talkspace, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $52 million and a market cap of $476.85 million. It has a P/E ratio of 188.00 and no dividend yield.

As of Jun 18, Talkspace, Inc. has a market capitalization of 476.85 million and reported net sales of 194.36 million with a net profit of 2.93 million over the latest four quarters. The balance sheet shows shareholder's funds of 117.39 million and total assets of 212.82 million.